Bio Rad Laboratories (BIO) Heads To Healthcare Conference, Is The Premium Already Priced In?

Bio-Rad Laboratories (BIO) heads into the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, with Executive VP and CFO Roop K. Lakkaraju presenting the company’s story to institutional investors and industry watchers.

Recent trading has been choppy for Bio-Rad Laboratories, with the share price slipping 2.18% over the last day and 4.94% over the past week, yet still showing a 30-day share price return of 3.51% and a 90-day share price return of 28.96% that points to strengthening momentum. At a latest share price of US$368.75, that move feeds into a year-to-date share price return of 20.79%. The 1-year total shareholder return of 28.98% contrasts with a 3-year total shareholder return that is slightly negative and a 5-year total shareholder return that is down 53.04%. This context frames the upcoming conference appearance and recent lobbying shift as part of a broader effort to reset how investors view the business and its risk profile.

Spot emerging peers riding similar conference and sector catalysts by scanning our curated 18 high quality undiscovered gems alongside Bio-Rad Laboratories.

Bulls see Bio-Rad Laboratories as a recovering life sciences platform after a sharp multi year drawdown, while bears point to mixed total returns and lobbying shifts. Which story does the current valuation actually support next?

Most Popular Narrative: 12.1% Overvalued

With Bio-Rad Laboratories changing hands at $368.75 against a narrative fair value of $329, the story hinges on modest growth assumptions and a rich earnings multiple.

Analysts are assuming Bio-Rad Laboratories's revenue will grow by 1.5% annually over the next 3 years.

Analysts expect earnings to reach $224.0 million (and earnings per share of $8.29) by about August 2029, up from $222.4 million today.

Read the complete narrative.

Want to see why such low single digit revenue and profit forecasts still support a premium P/E and higher fair value for Bio-Rad Laboratories? The narrative leans on gradual mix shift, firmer recurring income and a higher future earnings multiple that is well above the broader life sciences group. Curious which assumptions sit at the center of that calculation and how buybacks change the per share math? The full story joins these pieces together.

Result: Fair Value of $329 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the Bio-Rad Laboratories story can change sharply if weak instrument demand continues to compress margins or if China reimbursement and policy changes further pressure Clinical Diagnostics revenue.

Find out about the key risks to this Bio-Rad Laboratories narrative.

Next Steps

Uncertain where the Bio-Rad Laboratories story lands after the conference spotlight and recent returns reset expectations. Act quickly by reviewing the data and weighing that context against the 1 important warning sign.

Looking for more Bio-Rad Laboratories investment ideas?

If Bio-Rad Laboratories has your attention, do not stop here. Broadening your watchlist with other focused ideas can sharpen your decisions and reveal opportunities you might otherwise miss.

• Target potential value opportunities by scanning a curated set of 33 high quality undervalued stocks that combine solid fundamentals with pricing that may warrant a closer look.
• Prioritise resilience and capital preservation by reviewing a 11 resilient stocks with low risk scores that focuses on businesses with gentler risk profiles.
• Zero in on financial strength by assessing a list of solid balance sheet and fundamentals (23 results) that highlights companies built on sturdier balance sheets and healthier fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com